The hypothalamic-pituitary-adrenal (HPA) system plays an important role in stress response. Chronic stress is thought to induce neuronal damage and contribute to the pathogenesis of psychiatric disorders by causing dysfunction of the HPA system and promoting the production and release of glucocorticoids, including corticosterone and cortisol. Several clinical studies have demonstrated the efficacy of herbal medicines in treating psychiatric disorders; however, their effects on corticosterone-induced neuronal cell death remain unclear. Here, we used HT22 cells to evaluate the neuroprotective potential of herbal medicines used in neuropsychiatry against corticosterone-induced hippocampal neuronal cell death. Cell death was assessed using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) reduction and Live/Dead assays. Hangekobokuto, Kamikihito, Saikokaryukotsuboreito, Kamishoyosan, and Yokukansan were supplied in the form of water-extracted dried powders. Exposure of HT22 cells to ≥ 100 μM corticosterone decreased MTT values. Exposure to 500 μM corticosterone alone reduced MTT values to 18%, while exposure to 10 μM Mifepristone (RU486)-a glucocorticoid receptor antagonist-restored values to 36%. Corticosterone-induced cell death was partially suppressed by treatment with RU486. At 100 μg/mL, Hangekobokuto significantly suppressed the decrease in MTT values (15-32%) and increase in the percentage of ethidium homodimer-1-positive dead cells caused by corticosterone exposure (78-36%), indicating an inhibitory effect on cell death. By contrast, Kamikihito, Saikokaryukotsuboreito, Kamishoyosan, and Yokukansan did not affect corticosterone-induced cell death. Therefore, our results suggest that Hangekobokuto may ameliorate the onset and progression of psychiatric disorders by suppressing neurological disorders associated with increased levels of glucocorticoids.

01 Nov 2023·Journal of Cellular and Molecular Medicine

The effect of Banxia‐houpo decoction on CUMS‐induced depression by promoting M2 microglia polarization via TrkA/Akt signalling

Article

Author: Xia, Baomei ; Chen, Chang ; Xia, Changbo ; Liu, Li ; Yao, Guangda ; He, Xiaogang ; Zhang, Rong

AbstractIt has been reported that Banxia‐houpo decoction (BXHPD) serves as the anti‐depressant treatment for a mild and severe depressive disease with limited side effects. The present study was performed to evaluate the protective effect of BXHPD on chronic unpredicted mild stress (CUMS)‐induced depression and explore its effect on TrkA/Akt‐mediated microglia polarization. The CUMS procedure was carried out, and the mice were intragastrically treated with BXHPD once daily. The selective TrkA inhibitor GW441756 was applied to further investigate the role of TrkA in BXHPD‐mediated microglia polarization. The behaviour test including open field test (OFT), sucrose preference test (SPT), novelty‐suppressed feeding test (NSFT), tail suspension test (TST) and forced swim test (FST) was performed. The concentrations of pro‐inflammatory cytokines IL‐6, TNF‐α, IL‐1β, IL‐12 and anti‐inflammatory cytokines IL‐4, IL‐10 were determined using Enzyme‐linked immunosorbent assay. The population of Iba1+ cells and the length of microglia processes were observed under the fluorescence microscope. The mRNA expressions of Arg1, Ym1 and Fizzl1 were measured by PCR. The protein expressions of TrkA, p‐Tyr490‐TrkA, p‐Ser473‐Akt, p‐Ser473‐Akt1, p‐Ser474‐Akt2, p‐CREB and Jmjd3 were detected by western blot. Our results showed that BXHPD attenuated CUMS‐induced depressive‐like behaviour, promoted anti‐inflammatory cytokines, inhibited pro‐inflammatory cytokines, suppressed microglia activation, promoted M2 phenotype‐specific indices and upregulated the expressions of TrkA, p‐Tyr490‐TrkA, p‐Ser473‐Akt, p‐Ser473‐Akt1, p‐Ser474‐Akt2, p‐CREB and Jmjd3. The above beneficial effect of BXHPD can be blocked by TrkA inhibitor GW441756. This work demonstrated that BXHPD exerted an anti‐depressant effect by promoting M2 phenotype microglia polarization via TrkA/Akt pathway.

01 Jan 2022·Journal of Smooth Muscle Research

Hangekobokuto, a traditional Japanese herbal medicine, ameliorates postoperative ileus through its anti-inflammatory action

Article

Author: Tonooka, Miki ; Endo, Mari ; Hanawa, Toshihiko ; Oikawa, Tetsuro ; Odaguchi, Hiroshi ; Hori, Masatoshi

BACKGROUND/AIMSGastroprokinetic agents are used for patients with postoperative ileus (POI), and the Japanese traditional herbal medicine daikenchuto (DKT) is one such agent used in the clinical setting. POI is caused by inflammation. DKT and rikkunshito have anti-inflammatory abilities in addition to their gastroprokinetic effects. The efficacy of Kampo formulations, including hangekobokuto (HKT), in patients with POI has been reported recently. Several authors have described the efficacy of honokiol, the primary component of Magnoliae Cortex, in HKT in mouse models of POI. We therefore analyzed the effect of HKT on POI model mice to determine the similarities in the mechanism of action between HKT and DKT.METHODSHKT was administered orally to each mouse before and after intestinal manipulation was performed on the distal ileum. The gastrointestinal transit in vivo, leukocyte infiltration, and levels of inflammatory mediators, such as cytokines and chemokines, were analyzed.RESULTSHKT significantly inhibited the infiltration of neutrophils and macrophages and led to the recovery of delayed intestinal transit. In addition, it significantly decreased inducible nitric oxide synthase (iNOS) as well as honokiol levels, suggesting anti-inflammatory activity. However, it did not inhibit the increase in levels of interleukin (IL)-1beta and IL-6, which are related to iNOS induction. In contrast, HKT increased levels of nerve growth factor (NGF) and suppressed those of nuclear factor-κB (NFκB), which are related to iNOS induction, suggesting the possibility of a neuronal anti-inflammatory mechanism.CONCLUSIONSHKT exerted a POI-relieving effect similar to DKT in a murine POI model, and findings suggest that it may exert its anti-inflammatory activity through NGF.

100 Deals associated with Banxia Houpo Decoction

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Gastritis	JP	Kowa Yakutsu Y.K.	02 Sep 1986
Anxiety Disorders	JP	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986
Cough	JP	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986
Asthma	JP	Sanwa Shoyaku Co., Ltd.	18 Jul 1986
Bronchitis	JP	Sanwa Shoyaku Co., Ltd.	18 Jul 1986
Hoarseness	JP	Sanwa Shoyaku Co., Ltd.	18 Jul 1986
Whooping Cough	JP	Sanwa Shoyaku Co., Ltd.	18 Jul 1986

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Banxia Houpo Decoction

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation